Search Results 611-620 of 18557 for alopecia

1. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are ...

2. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer - Mayo Clinic

   ... alopecia * Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease * Evidence of active and uncontrolled hepatitis B ...

3. Bleomycin (injection route) - Mayo Clinic

   Bleomycin belongs to the general group of medicines called antineoplastics. It is used to treat several types of cancer, including cervix and uterus cancer, ...

4. DAREON™-9: A Study To Test How Well Different Doses Of BI 764532 Are Tolerated By People With Small Cell Lung Cancer When Taken Together With A Single Agent Chemotherapy - Mayo Clinic

   Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia ...

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester, MN ...

6. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

7. Phase 1 Study Of CLR 125 In Triple Negative Breast Cancer - Mayo Clinic

   * Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia, that in the opinion of investigator might be exacerbated by study ...

8. Open-label, Single Arm Trial Of BI 695502 In Patients With Previously Untreated Metastatic Colorectal Cancer - Mayo Clinic

   Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy); History or evidence ...

9. Phase II Study Of MEDI4736, Tremelimumab, And MEDI4736 In Combination W/ Tremelimumab Squamous Cell Carcinoma Of The Head And Neck - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

10. Dacarbazine (intravenous route, injection route) - Side effects & dosage - Mayo Clinic

    Dacarbazine belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin ...